Could This Combo Boost Response in Tough AML Cases? | Amir Fathi, MD

Could This Combo Boost Response in Tough AML Cases? | Amir Fathi, MD

Could This Anti‑Inflammatory Help Myelofibrosis Patients? | Andrew Kuykendall, MD

Could This Anti‑Inflammatory Help Myelofibrosis Patients? | Andrew Kuykendall, MD

VERIFY Study: Rusfertide Shows Long-Lasting Control | Andrew Kuykendall, MD

Surviving MDS: Why Blood Counts Matter! | Ira Zackon, MD

Surviving MDS: Why Blood Counts Matter! | Ira Zackon, MD

Older AML Treatment: New Insights From ASH! | Ira Zackon, MD

Older AML Treatment: New Insights From ASH! | Ira Zackon, MD

Can This Drug Improve MPN Blast-Phase Outcomes? | Anand Patel, MD

Bleximenib Breakthrough in High-Risk AML? | Hartmut Döhner, MD

Bleximenib Breakthrough in High-Risk AML? | Hartmut Döhner, MD

TKI + Inotuzumab: Could This Be a Better Treatment? | Anand Patel, MD

TKI + Inotuzumab: Could This Be a Better Treatment? | Anand Patel, MD

Improved Survival with Liso-cel in Relapsed Lymphoma | Manali Kamdar, MD

Promising Early Results: Allogeneic CAR-T for Relapsed Lymphoma! | Supriya Gupta, MD

Venetoclax + Inotuzumab: Changing the Game in Relapsed ALLL | Marlise Luskin, MD

Venetoclax + Inotuzumab: Changing the Game in Relapsed ALLL | Marlise Luskin, MD

Financial Strain & Delayed Treatment in Blood Cancers | Christopher Su, MD